Literature DB >> 16940124

Endocarditis caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: emergence of resistance to ciprofloxacin and piperacillin-tazobactam during treatment despite initial susceptibility.

Oren Zimhony1, Inna Chmelnitsky, Rita Bardenstein, Sorel Goland, Orly Hammer Muntz, Shiri Navon Venezia, Yehuda Carmeli.   

Abstract

Three episodes of bacteremia occurred in the course of prosthetic valve endocarditis caused by an extended-spectrum-beta-lactamase (ESBL)-producing Klebsiella pneumoniae strain. The second isolate developed resistance to ciprofloxacin and the third isolate to piperacillin-tazobactam (PIP-TZ) following sequential therapy with each agent. The first isolate was resistant to PIP-TZ only at high inocula, the second isolate acquired increased transcription of the acrA gene, and the third isolate became resistant to PIP-TZ due to loss of beta-lactamase inhibition by TZ. We question if and how PIP-TZ susceptibility should be reported for ESBL-producing Enterobacteriaceae.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16940124      PMCID: PMC1563546          DOI: 10.1128/AAC.00218-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  30 in total

1.  Nosocomial endocarditis due to extended-spectrum beta-lactamase-producing Klebsiella pneumoniae in a child.

Authors:  S E Shipton; M F Cotton; G Wessels; E Wasserman
Journal:  S Afr Med J       Date:  2001-04

2.  Variable susceptibility to piperacillin/tazobactam amongst Klebsiella spp. with extended-spectrum beta-lactamases.

Authors:  Gioia S Babini; Meifang Yuan; Lucinda M C Hall; David M Livermore
Journal:  J Antimicrob Chemother       Date:  2003-03       Impact factor: 5.790

3.  Evaluation of the Etest ESBL and the BD Phoenix, VITEK 1, and VITEK 2 automated instruments for detection of extended-spectrum beta-lactamases in multiresistant Escherichia coli and Klebsiella spp.

Authors:  Maurine A Leverstein-van Hall; Ad C Fluit; Armand Paauw; Adrienne T A Box; Sylvain Brisse; Jan Verhoef
Journal:  J Clin Microbiol       Date:  2002-10       Impact factor: 5.948

4.  qnrB, another plasmid-mediated gene for quinolone resistance.

Authors:  George A Jacoby; Kelley E Walsh; Debra M Mills; Victoria J Walker; Herin Oh; Ari Robicsek; David C Hooper
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

5.  AcrAB Efflux System: Expression and Contribution to Fluoroquinolone Resistance in Klebsiella spp.

Authors:  Annarita Mazzariol; Jessica Zuliani; Giuseppe Cornaglia; Gian Maria Rossolini; Roberta Fontana
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

6.  Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia.

Authors:  D L Paterson; L Mulazimoglu; J M Casellas; W C Ko; H Goossens; A Von Gottberg; S Mohapatra; G M Trenholme; K P Klugman; J G McCormack; V L Yu
Journal:  Clin Infect Dis       Date:  2000-03       Impact factor: 9.079

7.  Mechanism of plasmid-mediated quinolone resistance.

Authors:  John H Tran; George A Jacoby
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-09       Impact factor: 11.205

8.  Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae.

Authors:  K S Thomson; E S Moland
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

9.  Relative contributions of the AcrAB, MdfA and NorE efflux pumps to quinolone resistance in Escherichia coli.

Authors:  Shirley Yang; Sonia Rahmati Clayton; E Lynn Zechiedrich
Journal:  J Antimicrob Chemother       Date:  2003-03       Impact factor: 5.790

10.  Mutation rate and evolution of fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract infections.

Authors:  Patricia Komp Lindgren; Asa Karlsson; Diarmaid Hughes
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

View more
  21 in total

1.  Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment.

Authors:  Mario Tumbarello; Maurizio Sanguinetti; Eva Montuori; Enrico M Trecarichi; Brunella Posteraro; Barbara Fiori; Rita Citton; Tiziana D'Inzeo; Giovanni Fadda; Roberto Cauda; Teresa Spanu
Journal:  Antimicrob Agents Chemother       Date:  2007-03-26       Impact factor: 5.191

2.  Fatal endocarditis due to extended spectrum betalactamase producing Klebsiella terrigena in a liver transplant recipient.

Authors:  Hannes Goegele; Elfriede Ruttmann; Jaime Aranda-Michel; Reinhold Kafka; Ingrid Stelzmueller; Hans Hausdorfer; Robert Sawyer; Raimund Margreiter; Hugo Bonatti
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

3.  Optimal Piperacillin-Tazobactam Dosing Strategies against Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae.

Authors:  Henrietta Abodakpi; Kai-Tai Chang; Song Gao; Ana María Sánchez-Díaz; Rafael Cantón; Vincent H Tam
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

4.  Gram-negative endocarditis.

Authors:  Milagros P Reyes; Katherine C Reyes
Journal:  Curr Infect Dis Rep       Date:  2008-07       Impact factor: 3.725

5.  Diagnosis of E. coli tricuspid valve endocarditis: a case report.

Authors:  Takahiko Tsutsumi; Eiji Hiraoka; Kenji Kanazawa; Hozuka Akita; Lawrence J Eron
Journal:  Hawaii Med J       Date:  2010-12

6.  The Resistant-Population Cutoff (RCOFF): a New Concept for Improved Characterization of Antimicrobial Susceptibility Patterns of Non-Wild-Type Bacterial Populations.

Authors:  Giorgia Valsesia; Michael Hombach; Florian P Maurer; Patrice Courvalin; Malgorzata Roos; Erik C Böttger
Journal:  J Clin Microbiol       Date:  2015-03-11       Impact factor: 5.948

7.  Treatment with fluoroquinolones or with beta-lactam-beta-lactamase inhibitor combinations is a risk factor for isolation of extended-spectrum-beta-lactamase-producing Klebsiella species in hospitalized patients.

Authors:  Kenneth M Wener; Vered Schechner; Howard S Gold; Sharon B Wright; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2010-03-08       Impact factor: 5.191

Review 8.  The Use of Noncarbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase Infections.

Authors:  Pranita D Tamma; Jesus Rodriguez-Bano
Journal:  Clin Infect Dis       Date:  2017-04-01       Impact factor: 9.079

9.  A statistical approach for determination of disk diffusion-based cutoff values for systematic characterization of wild-type and non-wild-type bacterial populations in antimicrobial susceptibility testing.

Authors:  Giorgia Valsesia; Malgorzata Roos; Erik C Böttger; Michael Hombach
Journal:  J Clin Microbiol       Date:  2015-03-11       Impact factor: 5.948

10.  A Multinational, Preregistered Cohort Study of β-Lactam/β-Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae.

Authors:  Belén Gutiérrez-Gutiérrez; Salvador Pérez-Galera; Elena Salamanca; Marina de Cueto; Esther Calbo; Benito Almirante; Pierluigi Viale; Antonio Oliver; Vicente Pintado; Oriol Gasch; Luis Martínez-Martínez; Johann Pitout; Murat Akova; Carmen Peña; José Molina; Alicia Hernández; Mario Venditti; Nuria Prim; Julia Origüen; German Bou; Evelina Tacconelli; Mario Tumbarello; Axel Hamprecht; Helen Giamarellou; Manel Almela; Federico Pérez; Mitchell J Schwaber; Joaquín Bermejo; Warren Lowman; Po-Ren Hsueh; Marta Mora-Rillo; Clara Natera; Maria Souli; Robert A Bonomo; Yehuda Carmeli; David L Paterson; Alvaro Pascual; Jesús Rodríguez-Baño
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.